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Purpose: To investigate whether single nucleotide polymorphisms (SNPs) in the vascular endothelial growth factor
(VEGF) gene are associated with diabetic retinopathy (DR) in a cohort of Chinese patients with type 2 diabetes mellitus
(T2DM).
Methods: A total of 268 patients with T2DM (129 with DR and 139 without DR) were recruited and enrolled in the study.
Patients with T2DM were assigned to a DR group or a diabetic-without-retinopathy group, based on the duration of diabetes
and grading of fundus images. Genotypes of eight SNPs in the VEGF gene (rs699947, rs833061, rs13207351, rs2010963,
rs833069, rs2146323, rs3025021, and rs3025039) were analyzed using a mass-array genotyping system, and an association
study was performed.
Results: After adjusting for covariates, a significant association of DR was observed with the homozygous genotype of
the minor allele for promoter SNPs rs699947 (odds ratio (OR)=3.54, 95% confidence interval (CI): 1.12–11.19), rs833061
(OR=3.72, 95% CI: 1.17–11.85) and rs13207351 (OR=3.76, 95% CI: 1.21–11.71). A significant association of DR was
also observed with haplotype ACA, as defined by minor alleles of promoter SNPs rs699947, rs833061, and rs13207351
(OR=1.52, 95% CI: 1.03–2.24), and haplotype GAA, as defined by SNPs rs2010963, rs833069, and rs2146323 (OR=1.62,
95% CI: 1.08–2.41).
Conclusions: Our data suggest that polymorphisms in the promoter region of the VEGF gene increase the risk of DR in
Chinese patients with T2DM.
Diabetic  retinopathy  (DR)  accounts  for  8%  of  legal
blindness in the United States, making it the leading cause of
legal blindness in working-age adults [1]. The accumulated
evidence suggests that the severity and progression of DR are
influenced by genetic and environmental factors. Vascular
endothelial  growth  factor  (VEGF),  an  endothelial  cell-
specific mitogen, has been implicated as a major contributor
to  the  development  of  DR  [2,3].  Both  hypoxia  and
hyperglycemia  are  potent  stimuli  for  VEGF  protein
expression [4-6], and the vitreous concentration of VEGF has
been shown to be higher in patients with DR [7-10]. Elevated
VEGF  and  its  receptor  expression  have  also  been
demonstrated  in  diabetic  retinas  [11].  Moreover,  VEGF
antagonists are able to reduce retinal vascular permeability
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and neovascularization, thus inhibiting the development of
DR [12,13].
The human VEGF gene, located on chromosome 6, is
highly  polymorphic,  with  seven  introns  and  eight  exons.
Single nucleotide polymorphisms (SNPs) in the promoter and
the 5′ untranslated region (UTR) of the VEGF gene have been
shown  to  influence  the  expression  of  the  VEGF  protein
[14-22]. Several longitudinal [23,24] and case-control [14,
18,22,25-32] studies also suggest that SNPs in VEGF gene
mediate  genetic  predisposition  to  DR.  The  results  from
different studies, however, are conflicting and inconclusive
[14,23-34].  In  the  present  study,  we  aimed  to  investigate
whether  common  polymorphisms  in  the  VEGF  gene  are
associated with DR in a cohort of Chinese patients with type
2 diabetic mellitus (T2DM).
METHODS
Study  participants  and  clinical  evaluation:  Patients  with
T2DM  were  recruited  between  November  2009  and
September  2010  from  the  Desheng  community  of  urban
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3088Beijing.  The  study  protocol  was  approved  by  the  Ethics
Committee of Beijing Tongren Hospital and adhered to the
tenets  of  the  Declaration  of  Helsinki.  Written  informed
consent  was  obtained  from  all  participants  before  their
enrollment. Diabetes was defined as a self-reported history of
physician-diagnosed  T2DM  treated  with  insulin,  oral
hypoglycemic agents, or diet only, or by a fasting plasma
glucose (FPG) concentration of 7.0 mmol/l (126 mg/dl) or
more  in  at  least  two  previous  examinations  or  a  random
plasma glucose concentration of ≥11.1 mmol/l (200 mg/dl).
All subjects underwent a standardized evaluation consisting
of a questionnaire, ocular and anthropometric examinations,
and  a  laboratory  test.  The  questionnaire  elicited  basic
information (age, sex, ethnicity, income, education), lifestyle
information  (such  as  smoking  and  alcohol  intake),  health
status information (such as the use of insulin therapy and any
history of systemic diseases), and family history of diseases.
Anthropometric parameters included bodyweight and height,
waist and hip circumference, and three measurements, 5 min
apart, of blood pressure in a resting state. Body mass index
(BMI, kg/m2) [35] and waist-to-hip ratio were calculated. A
comprehensive  ophthalmological  examination  included
corrected visual acuity, slit-lamp biomicroscopy, and fundus
photography  [36,37].  Seven  fields  30°  color  fundus
photographs with stereoscopic images of the optic disc and
macula were taken through the dilated pupils of each patient
using  a  digital  fundus  camera  (Zeiss  Visucam  Pro,
Oberkochen, Germany).
Based on the duration of diabetes and grading of fundus
photographs, patients were assigned to the diabetic-without-
retinopathy (DWR) group if they had more than 10 years’
duration of T2DM with no signs of DR (microaneurysms,
hemorrhages, exudates) or if they had more than 15 years’
duration  of  T2DM  with  fewer  than  five  microaneurysms
[29,38]. Patients with five or more microaneurysms in at least
one eye were assigned to the DR group. Patients who did not
meet the DWR or DR criteria were excluded from this study.
The duration of diabetes was defined as the interval between
the first diagnosis of diabetes and the time of enrollment in
the present study.
Laboratory assays: Fasting blood samples were collected for
measurement  of  FPG,  glycosylated  hemoglobin  A1c
(HbA1c), creatinine, uric acid, and lipid profile (levels of total
cholesterol, triglycerides, and high-density and low-density
lipoprotein  cholesterol),  which  were  measured  in  an
automated  system  with  reagents  for  routine  biomarkers.
HbA1c was assessed by the enzymatic method using a Hitachi
analyzer  7080  (Ibaraki,  Japan).  A  first-void,  midstream
morning spot urine sample was collected, and albuminuria
was measured by immunonephelometry with a Roche/Cobas
C501 analyzer (Ibaraki, Japan). High albuminuria was defined
as ≥20 mg/l [39].
Genotyping  for  vascular  endothelial  growth  factor
polymorphisms:  Blood  samples  were  collected  from  all
participants and stored at −80 °C before DNA extraction.
Genomic DNA was isolated from venous blood leukocytes
using  a  genomic  DNA  extraction  and  purification  kit
TABLE 1. CLINICAL AND BIOCHEMICAL MARKERS FOR THE STUDIED GROUPS.
Clinical characteristics DWR (n=139) DR (n=129) p value
Age of diabetic onset (years) 50.45±8.00 48.68±9.58 0.1
Sex (Male/Female) 58/81 57/72 0.78
Duration of diabetes (years) 15.06±4.38 14.59±7.52 0.52
BMI (kg/m2) 24.55±4.00 24.79±4.36 0.63
WHR 0.92±0.06 0.93±0.07 0.37
High albuminuria(-/+) 121/17 81/48 < 0.001
Systolic blood pressure (mmHg) 136±16.97 137.1±16.15 0.59
Diastolic blood pressure (mmHg) 77.38±8.82 78.92±10.05 0.33
Insulin therapy (yes/no) 47/92 81/48 < 0.001
HbA1c (%) 7.07±1.39 7.93±1.67 < 0.001
FPG (mmol/l) 8.23±2.46 9.23±2.97 0.003
Creatinine (µmol/l) 65.14±16.49 71.49±24.42 0.02
Uric acid (µmol/l) 275.8±77.83 277.7±68.38 0.84
Cholesterol (mmol/l) 5.22±0.95 5.26±1.13 0.7
Triglycerides (mmol/l) 1.67±1.09 1.67±1.17 0.75
HDL cholesterol (mmol/l) 1.21±0.29 1.23±0.32 0.65
LDL cholesterol (mmol/l) 3.08±0.79 3.08±0.86 0.98
        The data are expressed as mean±standard deviation (SD) or number of subjects. Differences between diabetic retinopathy (DR)
        and diabetic without retinopathy (DWR) groups were compared using t-test or χ2 test. BMI, body mass index; WHR, waist and
        hip ratio; HbA1c, glycosylated hemoglobin A1c; FPG, fasting plasma glucose; HDL, high-density lipoprotein; LDL, low-density
        lipoprotein.
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3089(TIANamp Swab DNA Kit; Tiangen Biotech, Beijing, China).
Eight SNPs in the VEGF gene (NCBI Reference Sequence:
NG008732.1)  were  genotyped,  including  rs699947
(−2578C>A) at the promoter region, rs833061 (−1498T>C)
at  the  promoter  region,  rs13207351  (−1190G>A)  at  the
promoter  region,  rs2010963  (−634C>G)  at  5′  UTR,
rs833069 (3596A>G) at intron 2, rs2146323 (6112C>A) at
intron 2, rs3025021 (10180T>C) at intron 6, and rs3025039
(13553C>T) at 3′ UTR. The nucleotide sequence variation in
all SNPs was numbered from the start of translation. Study
participants were genotyped for the SNPs using Sequenom
MassARRAY technology (Bioyong Technologies, Beijing,
China).
Statistics:  Statistical  analysis  was  performed  using  the  R
statistical  analysis  package.  Baseline  characteristics  of
diabetic patients in the DR and DWR groups were compared
using a t-test for continuous variables or a chi-square test for
categorical  variables.  The  genotype  frequencies  of  VEGF
were checked for the Hardy–Weinberg equilibrium using a
chi-square test. The chi-square test was also used to analyze
the distribution of genotypes and alleles. When the expected
frequency was less than 5, Fisher’s exact test was used. The
pairwise  linkage  disequilibrium  was  calculated  using
Haploview, version 4.2 (Broad Institute, Cambridge, MA)
[40]. Univariate and multivariate logistic regression analyses
were performed to identify the association between VEGF
SNPs/haplotypes  and  the  presence  of  DR.  Results  were
expressed as p values, odds ratios (OR), and 95% confidence
intervals (CI). Statistical significance was set at p<0.05.
RESULTS
A total of 268 patients (129 in the DR group and 139 in the
DWR group) were selected for the present study. Clinical
features  of  the  study  subjects  are  presented  in  Table  1.
Compared  with  the  DWR  group,  those  with  DR  had
TABLE 2. ALLELE AND GENOTYPE FREQUENCIES OF VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF) POLYMORPHISMS IN THE STUDIED GROUPS.
SNP Location of SNPs Sample size Allele and genotype DR DWR p value
rs699947 Promoter 267 A 80 (31.0) 61 (22.1) 0.020
      CC 66 (51.2) 82 (59.4) 0.022
      CA 47 (36.4) 51 (37.0)
      AA 16 (12.4) 5 (3.6)
        H-W p=0.10 H-W p=0.47
rs833061 Promoter 265 C 78 (30.7) 62 (22.5) 0.032
      TT 65 (51.2) 81 (58.7) 0.021
      CT 46 (36.2) 52 (37.7)
      CC 16 (12.6) 5 (3.6)
        H-W p=0.10 H-W p=0.47
rs13207351 Promoter 264 A 80 (31.0) 61 (22.6) 0.029
      GG 66 (51.2) 79 (58.5) 0.017
      GA 46 (35.7) 51 (37.8)
      AA 17 (13.2) 5 (3.7)
        H-W p=0.069 H-W p=0.47
rs2010963 5′ UTR 266 C 112 (43.4) 124 (45.3) 0.67
      GG 36 (27.9) 39 (28.5) 0.61
      GC 74 (57.4) 72 (52.6)
      CC 19 (14.7) 26 (19)
        H-W p=0.073 H-W p=0.50
rs833069 Intron 2 268 G 117 (45.3) 130 (46.8) 0.74
      GG 23 (17.8) 29 (20.9) 0.80
      GA 71 (55) 72 (51.8)
      AA 35 (27.1) 38 (27.3)
        H-W p=0.22 H-W p=0.74
rs2146323 Intron 2 266 A 76 (29.7) 58 (21.0) 0.021
      CC 67 (52.3) 88 (63.8) 0.09
      CA 46 (35.9) 42 (30.4)
      AA 15 (11.7) 8 (5.8)
        H-W p=0.14 H-W p=0.44
rs3025021 Intron 6 264 C 225 (87.9) 219 (80.5) 0.021
      TT 4 (3.1) 7 (5.1) 0.067
      CT 23 (18) 39 (28.7)
      CC 101 (78.9) 90 (66.2)
        H-W p=0.031 H-W p=0.28
rs3025039 3′ UTR 268 T 50 (19.4) 53 (19.1) 0.93
      CC 83 (64.3) 89 (64.0) 0.88
      CT 42 (32.6) 47 (33.8)
      TT 3 (3.1) 3 (2.2)
        H-W p=0.79 H-W p=0.29
        Data are expressed as number (%). Genotype distributions for SNPs were in Hardy–Weinberg (H-W) equilibrium, except
        rs3025021 in diabetic retinopathy (DR) group. The p value represents comparison between DR and diabetic without retinopathy
        (DWR) groups, using χ2 or Fisher’s exact test. UTR indicates untranslated region.
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3090significantly  higher  levels  of  creatinine  (p=0.02),  FPG
(p=0.003), and HbA1c (p<0.001). Patients in the DR group
had higher percentages of high albuminuria (p<0.001) and
were more likely to use insulin (p<0.001) than DWR patients.
There was no statistically significant difference between the
DR and DWR groups in terms of gender, duration of diabetes,
age of diabetic onset, BMI, waist-to-hip ratio, blood pressure,
serum levels of uric acid, or lipid profile.
Table 2 presents a comparison of genotype and allele
frequencies between the DWR and DR groups. More than
98% of the subjects were successfully genotyped for each SNP
using  mass  spectrometry.  The  genotype  distribution  of
rs3025021 was in Hardy–Weinberg equilibrium in the DWR
group (p=0.28) but showed a slight deviation from it in the
DR group (p=0.031). The genotype distribution for all the
other seven SNPs tested was in Hardy–Weinberg equilibrium
in  both  the  DR  and  DWR  groups  (p≥0.069).  A  strong
association  with  DR  was  detected  for  SNPs  rs699947,
rs833061,  and  rs13207351  at  the  promoter  region  of  the
VEGF gene. Compared to the DWR group, the DR group had
significantly higher frequencies for the A allele of rs699947
(p=0.020), the C allele of rs833061 (p=0.032), and the A allele
of rs13207351 (p=0.029). The genotypic distribution between
the  DR  and  DWR  groups  was  statistically  significantly
different for rs699947 (p=0.022), rs833061 (p=0.021), and
rs13207351 (p=0.017). Moreover, a statistically significant
difference between the DR and DWR groups was observed in
the allele frequency for intronic SNPs rs2146323 (p=0.021)
and  rs3025021  (p=0.021);  however,  the  distribution  of
genotypes  was  only  marginally  significant  for  rs2146323
(p=0.09) and rs3025021 (p=0.067). No statistically significant
difference was found for the allele frequencies or genotypic
distributions in SNPs rs833069, rs3025039, and rs2010963.
Table  3  presents  data  from  the  logistic  regression
analysis. After adjusting for the age of diabetic onset, high
albuminuria, insulin use, HbA1c, FPG, and creatinine levels,
the association with DR remained statistically significant for
the homozygous genotype of the minor alleles at the promoter
SNPs rs699947 (OR=3.54; 95% CI: 1.12–11.19), rs833061
(OR=3.72; 95% CI: 1.17–11.85), and rs13207351 (OR=3.76;
95% CI: 1.21–11.71). No statistically significant association
with  DR  was  observed  after  the  adjustment  for  the
homozygous genotype of minor alleles at the intronic SNPs
rs3025021  (OR=2.25;  95%  CI:  0.81–6.29)  or  rs2146323
(OR=0.93; 95% CI: 0.23–3.82).
The linkage disequilibrium analysis revealed two SNP
blocks (Figure 1). Block 1 included three promoter SNPs:
rs699947, rs833061, and rs13207351. Block 2 included the
SNPs  rs2010963  at  5′  UTR,  rs833069  at  intron  2,  and
rs2146323 at intron 2. Five major haplotypes with frequencies
of more than 0.03 were estimated, and each was compared
between the DR and DWR groups (Table 4). In block 1, the
frequency of haplotype ACA, defined by the minor alleles of
the promoter SNPs rs699947, rs833061, and rs13207351, was
30.7%  in  the  DR  group  and  22.6%  in  the  DWR  group
(p=0.036,  OR=1.52,  95%  CI:  1.03–2.24).  In  block  2,  the
frequency of haplotype GAA, defined by the minor alleles of
the  SNPs  rs2010963,  rs833069,  and  rs2146323,  was
significantly higher in the DR group than in the DWR group
(p=0.018, OR=1.62, 95% CI: 1.08–2.41).
DISCUSSION
In the present study, we investigated the possible association
between VEGF polymorphisms and the presence of DR in a
well defined cohort of Chinese patients with T2DM. Eight
SNPs, previously shown to be associated with altered VEGF
protein production or risk of DR [14-22], were selected for the
TABLE 3. ASSOCIATION BETWEEN VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF) POLYMORPHISMS AND RISK OF DIABETIC RETINOPATHY IN PATIENTS WITH TYPE 2 DIABETES MELLITUS.
SNP Location of SNPs Genotype Crude OR (95% CI) Adjusted OR (95% CI) p (Wald's test)
rs699947 Promoter CC 1 1  
    CA 1.14 (0.69, 1.91) 1.04 (0.59, 1.85) 0.89
    AA 3.98 (1.38, 11.42) 3.54 (1.12, 11.19) 0.031
rs833061 Promoter TT 1 1  
    CT 1.10(0.66, 1.84) 1.00 (0.56, 1.79) 0.99
    CC 3.99 (1.39, 11.46) 3.72 (1.17, 11.85) 0.026
rs13207351 Promoter GG 1 1  
    AG 1.08 (0.64, 1.81) 0.98 (0.55, 1.74) 0.95
    AA 4.07 (1.43, 11.62) 3.76 (1.21, 11.71) 0.02
rs2146323 Intron 2 CC 1 1  
    CA 1.46 (0.86, 2.47) 1.31 (0.73, 2.35) 0.37
    AA 2.43 (0.97, 6.08) 2.25 (0.81, 6.29) 0.12
rs3025021 Intron 6 TT 1 1  
    CT 0.54 (0.30, 0.97) 0.50 (0.11, 2.27) 0.37
    CC 0.59 (0.16, 2.17) 1.08 (0.26, 4.44) 0.92
        Multiple logistic regression analysis was used to calculate odds ratio (OR) and 95% confidence interval (CI) by comparing
        diabetic retinopathy (DR) group with diabetic without retinopathy (DWR) group. Adjusted OR represents data after adjustment
        for covariates including the age of diabetic onset, high albuminuria, insulin use, glycosylated hemoglobin A1c, fasting plasma
        glucose, and creatinine.
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3091study. Our data support the observation that polymorphisms
in the promoter region of the VEGF gene are associated with
the risk of DR in diabetic patients.
As  previously  noted,  the  association  between  VEGF
polymorphisms  and  the  presence  or  severity  of  DR  is
inconclusive and conflicting either in the same or different
populations [14,18,22-34]. As shown in Table 5, for example,
rs833061  at  the  promoter  region  had  been  shown  to  be
associated with the risk of DR in an Indian study [29], but such
an  association  was  not  reported  among  Japanese  [14]  or
Caucasians  [22].  Another  promoter  polymorphism
rs13207351 was found to be associated with DR in Caucasians
[27]  but  not  in  Indian  or  Japanese  populations  [14,29].
Additionally, rs699947 at the promoter region was associated
with DR in Koreans [32] and marginally in Japanese [26,31],
but the data were inconclusive for Caucasians [23,25,33]. The
Figure 1. Linkage disequilibrium plot
generated by Haploview 4.2 software.
Two  haplotype  blocks  (bold)  were
identified  for  single  nucleotide
polymorphisms (SNPs) in the vascular
endothelial growth factor (VEGF) gene.
Linkage  disequilibrium  (LD)  is
displayed  as  pairwise  D’  values
multiplied by 100 and given for each
SNP  combination  [40].  Shading
represents  the  magnitude  and
significance of pairwise LD, with a red-
to-white  gradient  reflecting  higher-to-
lower LD values. Red diamond without
a number corresponds to D’ values of
1.0.
TABLE 4. HAPLOTYPE ASSOCIATION ANALYSIS BETWEEN VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF) POLYMORPHISMS AND RISK OF
DIABETIC RETINOPATHY IN PATIENTS WITH TYPE 2 DIABETES MELLITUS.
Haplotype blocks DR group (%) DWR group (%) OR (95%CI) χ2 p value
Block 1
CTG 69.3 77.4 0.66 (0.45, 0.97) 4.42 0.036
ACA 30.31 22.6 1.52 (1.03, 2.24) 4.42 0.036
Block 2
CGC 42.9 44.9 0.95 (0.67, 1.34) 0.1 0.76
GAC 24.2 32.1 0.69 (0.47, 1.01) 3.73 0.054
GAA 29.3 20.8 1.62 (1.08, 2.41) 5.59 0.018
        Data were given as frequency of each haplotype within diabetic retinopathy (DR) group or diabetic without retinopathy (DWR)
        group. Block 1 included promoter SNPs rs699947, rs833061, and rs13207351, whereas block 2 included SNPs rs2010963 at 5′
        UTR, rs833069 at intron 2, and rs2146323 at intron 2. Only haplotypes with frequency over 3% were included in this table. OR
        indicates odds ratio and CI refers to confidence interval.
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.disparities among the various studies may be due to sampling
bias,  differences  in  the  inclusion  criteria  of  cases,
demographic factors, or differences in ethnic backgrounds
[41,42]. In the present study of Chinese patients with T2DM,
the three SNPs tested—rs699947,rs833061, and rs13207351
—at  the  VEGF  promoter  region  showed  significant
associations with DR susceptibility. Compared to the wild-
type genotypes, the homozygous genotype of the minor alleles
at  rs699947,rs833061,  and  rs13207351  conferred,
respectively, 3.54-, 3.72-, and 3.76-fold increases in the risk
of DR in the study cohort. These same three SNPs showed
strong linkage disequilibrium. Haplotypes containing minor
alleles of these three promoter SNPs (A for rs699947, C for
rs833061,  and  A  for  rs13207351)  were  also  significantly
associated with the risk of DR in the present study, suggesting
that the association might lie within the linkage disequilibrium
bin rather than with the individual SNPs [25,43].
Other  SNPs  at  the  intron  region,  where  there  can  be
intronic  enhancers  or  silencers  that  regulate  VEGF
transcription  [27],  have  not  been  extensively  investigated
[23,24,27]. In the present study, the mutant alleles of two
intronic SNPs rs2146323 and rs3025021 showed significant
association  with  DR.  However,  difference  in  genotype
distribution of these two intronic SNPs between DR and DWR
groups was only marginally significant in the study cohort.
Since  previous  studies  on  these  two  intronic  SNPs  also
generated  contradicting  results  in  Caucasians  [23,27]  and
Japanese [24], their role in the pathogenesis of DR would need
to be further explored. We did not find associations between
DR susceptibility and the other three tested SNPs (rs833069,
rs3025039, and rs2010963) in the present study.
The  mechanism  through  which  SNPs  affect  DR
susceptibility  is  not  known.  However,  promoter  SNPs
rs699947 and rs833061 have been reported to alter the VEGF
promoter activity or affect levels of mRNA expression [15,
17,19-21].  Patients  carrying  the  risk  C  allele  of  VEGF
polymorphism  rs833061  have  been  shown  to  exhibit
increased VEGF promoter activity [15,19]. The functional
role of rs699947 is reported contradictive among studies, with
patients carrying the C allele genotype showing both low
[20]  and  high  [17,21]  VEGF  levels.  One  of  the  possible
explanations for the conflicting results of functional studies
may lie in the fact that it is not an individual SNP but a
combined haplotype that is more important influencing the
gene function and DR susceptibility. Haplotypes might be
more predictive and informative than individual SNPs [44].
In summary, our data suggest that the SNPs rs699947,
rs833061,  and  rs13207351  at  the  promoter  region  of  the
VEGF gene might predispose Chinese patients with T2DM to
the risk of DR. However, this is a small sample study, and
further studies with a larger sample size are needed to confirm
this observation. Moreover, functional studies are needed to
understand the mechanisms by which VEGF polymorphisms
alter susceptibility to DR.
ACKNOWLEDGMENTS
This work was supported by the National Basic Research
Program of China (973 Program) Grant 2007CB512201 and
the Beijing Municipal Health Bureau Grant 2009208.
REFERENCES
1. Congdon NG, Friedman DS, Lietman T. Important causes of
visual impairment in the world today. Journal of the American
Medical Association 2003; 290:2057-60. [PMID: 14559961]
2. Penn JS, Madan A, Caldwell RB, Bartoli M, Caldwell RW,
Hartnett  ME.  Vascular  endothelial  growth  factor  in  eye
disease.  Prog  Retin  Eye  Res  2008;  27:331-71.  [PMID:
18653375]
3. Wirostko B, Wong TY, Simo R. Vascular endothelial growth
factor and diabetic complications. Prog Retin Eye Res 2008;
27:608-21. [PMID: 18929676]
4. Frank  RN.  Diabetic  retinopathy.  N  Engl  J  Med  2004;
350:48-58. [PMID: 14702427]
5. Qazi  Y,  Maddula  S,  Ambati  BK.  Mediators  of  ocular
angiogenesis. J Genet 2009; 88:495-515. [PMID: 20090210]
6. Tilton  RG,  Kawamura  T,  Chang  KC,  Ido  Y,  Bjercke  RJ,
Stephan CC, Brock TA, Williamson JR. Vascular dysfunction
induced by elevated glucose levels in rats is mediated by
vascular  endothelial  growth  factor.  J  Clin  Invest  1997;
99:2192-202. [PMID: 9151791]
7. Adamis AP, Miller JW, Bernal MT, Damico DJ, Folkman J,
Yeo TK, Yeo KT. Increased vascular endothelial growth-
factor levels in the vitreous of eyes with proliferative diabetic-
retinopathy. Am J Ophthalmol 1994; 118:445-50. [PMID:
7943121]
8. Aiello LP, Avery RL, Arrigg PG, Keyt BA, Jampel HD, Shah
ST, Pasquale LR, Thieme H, Iwamoto MA, Park JE, Nguyen
HV, Aiello LM, Ferrara N, King GL. Vascular endothelial
growth-factor  in  ocular  fluid  of  patients  with  diabetic-
retinopathy and other retinal disorders. N Engl J Med 1994;
331:1480-7. [PMID: 7526212]
9. Wang X, Wang G, Wang Y. Intravitreous vascular endothelial
growth factor and hypoxia-inducible factor 1a in patients with
proliferative diabetic retinopathy. Am J Ophthalmol 2009;
148:883-9. [PMID: 19837381]
10. Yoshimura T, Sonoda KH, Sugahara M, Mochizuki Y, Enaida
H, Oshima Y, Ueno A, Hata Y, Yoshida H, Ishibashi T.
Comprehensive analysis of inflammatory immune mediators
in vitreoretinal diseases. PLoS ONE 2009; 4:e8158. [PMID:
19997642]
11. Ishida S, Shinoda K, Kawashima S, Oguchi Y, Okada Y, Ikeda
E. Coexpression of vegf receptors vegf-r2 and neuropilin-1 in
proliferative diabetic retinopathy. Invest Ophthalmol Vis Sci
2000; 41:1649-56. [PMID: 10845581]
12. Aiello LP, Pierce EA, Foley ED, Takagi H, Chen H, Riddle L,
Ferrara  N,  King  GL,  Smith  LEH.  Suppression  of  retinal
neovascularization  in-vivo  by  inhibition  of  vascular
endothelial growth-factor (vegf) using soluble vegf-receptor
chimeric  proteins.  Proc  Natl  Acad  Sci  USA  1995;
92:10457-61. [PMID: 7479819]
13. Konopatskaya O, Churchill A, Harper S, Bates DO, Gardiner
T. Vegf(165)b, an endogenous c-terminal splice variant of
vegf, inhibits retinal neovascularization in mice. Mol Vis
2006; 12:626-32. [PMID: 16735996]
Molecular Vision 2011; 17:3088-3096 <http://www.molvis.org/molvis/v17/a332> © 2011 Molecular Vision
309414. Awata T, Inoue K, Kurihara S, Ohkubo T, Watanabe M, Inukai
K, Inoue I, Katayama S. A common polymorphism in the 5 '-
untranslated  region  of  the  vegf  gene  is  associated  with
diabetic  retinopathy  in  type  2  diabetes.  Diabetes  2002;
51:1635-9. [PMID: 11978667]
15. Watson  CJ,  Webb  NJA,  Bottomley  MJ,  Brenchley  PEC.
Identification  of  polymorphisms  within  the  vascular
endothelial  growth  factor  (vegf)  gene:  Correlation  with
variation  in  vegf  protein  production.  Cytokine  2000;
12:1232-5. [PMID: 10930302]
16. Renner W, Kotschan S, Hoffmann C, Obermayer-Pietsch B,
Pilger E. A common 936 c/t mutation in the gene for vascular
endothelial  growth  factor  is  associated  with  vascular
endothelial growth factor plasma levels. J Vasc Res 2000;
37:443-8. [PMID: 11146397]
17. Szeto CC, Chow KM, Poon P, Szeto YK, Wong TYH, Li PKT.
Genetic  polymorphism  of  vegf:  Impact  on  longitudinal
change  of  peritoneal  transport  and  survival  of  peritoneal
dialysis  patients.  Kidney  Int  2004;  65:1947-55.  [PMID:
15086939]
18. Kim HW, Ko GJ, Kang YS, Lee MH, Song HK, Kim HK, Cha
DR.  Role  of  the  vegf  936  c/t  polymorphism  in  diabetic
microvascular  complications  in  type  2  diabetic  patients.
Nephrology (Carlton) 2009; 14:681-8. [PMID: 19796028]
19. Stevens  A,  Soden  J,  Brenchley  PE,  Ralph  S,  Ray  DW.
Haplotype  analysis  of  the  polymorphic  human  vascular
endothelial growth factor gene promoter. Cancer Res 2003;
63:812-6. [PMID: 12591731]
20. Koukourakis  MI,  Papazoglou  D,  Giatromanolaki  A,
Bougioukas G, Maltezos E, Siviridis E. Vegf gene sequence
variation defines vegf gene expression status and angiogenic
activity in non-small cell lung cancer. Lung Cancer 2004;
46:293-8. [PMID: 15541813]
21. Shahbazi M, Fryer AA, Pravica E, Brogan IJ, Ramsay HM,
Hutchinson  IV,  Harden  PN.  Vascular  endothelial  growth
factor gene polymorphisms are associated with acute renal
allograft  rejection.  J  Am  Soc  Nephrol  2002;  13:260-4.
[PMID: 11752046]
22. Szaflik JP, Wysocki T, Kowalski M, Majsterek I, Borucka AI,
Blasiak  J,  Szaflik  J.  An  association  between  vascular
endothelial growth factor gene promoter polymorphisms and
diabetic  retinopathy.  Graefes  Arch  Clin  Exp  Ophthalmol
2008; 246:39-43. [PMID: 17849138]
23. Al-Kateb H, Mirea L, Xie XL, Sun L, Liu M, Chen HT, Bull
SB, Boright AP, Paterson AD, Group DER. Multiple variants
in vascular endothelial growth factor (vegfa) are risk factors
for time to severe retinopathy in type 1 diabetes - the dcct/edic
genetics study. Diabetes 2007; 56:2161-8. [PMID: 17513698]
24. Nakanishi K, Watanabe C. Single nucleotide polymorphisms of
vascular endothelial growth factor gene intron 2 are markers
for early progression of diabetic retinopathy in japanese with
type 1 diabetes. Clin Chim Acta 2009; 402:171-5. [PMID:
19263526]
25. Abhary S, Burdon KP, Gupta A, Lake S, Selva D, Petrovsky N,
Craig  JE.  Common  sequence  variation  in  the  vegfa  gene
predicts risk of diabetic retinopathy. Invest Ophthalmol Vis
Sci 2009; 50:5552-8. [PMID: 19553626]
26. Nakamura S, Iwasaki N, Funatsu H, Kitano S, Iwamoto Y.
Impact  of  variants  in  the  vegf  gene  on  progression  of
proliferative  diabetic  retinopathy.  Graefes  Arch  Clin  Exp
Ophthalmol 2009; 247:21-6. [PMID: 18709380]
27. Churchill AJ, Carter JG, Ramsden C, Turner SJ, Yeung A,
Brenchley  PEC,  Ray  DW.  Vegf  polymorphisms  are
associated  with  severity  of  diabetic  retinopathy.  Invest
Ophthalmol Vis Sci 2008; 49:3611-6. [PMID: 18441306]
28. Ray D, Mishra M, Ralph S, Read I, Davies R, Brenchley P.
Association  of  the  vegf  gene  with  proliferative  diabetic
retinopathy but not proteinuria in diabetes. Diabetes 2004;
53:861-4. [PMID: 14988276]
29. Suganthalakshmi  B,  Anand  R,  Kim  R,  Mahalakshmi  R,
Karthikprakash  S,  Namperumalsamy  P,  Sundaresan  P.
Association of vegf and enos gene polymorphisms in type 2
diabetic  retinopathy.  Mol  Vis  2006;  12:336-41.  [PMID:
16636650]
30. Errera FIV, Canani LH, Silva MER, Yeh E, Takahashi W,
Santos KG, Souto KEP, Tschiedel B, Roisenberg I, Gross JL,
Passos-Bueno MR. Functional vascular endothelial growth
factor −634g > c snp is associated with proliferative diabetic
retinopathy - a case-control study in a brazilian population of
european ancestry. Diabetes Care 2007; 30:275-9. [PMID:
17259494]
31. Awata T, Kurihara S, Takata N, Neda T, Iizuka H, Ohkubo T,
Osaki M, Watanabe M, Nakashima Y, Inukai K, Inoue I,
Kawasaki I, Mori K, Yoneya S, Katayama S. Functional vegf
c-634g  polymorphism  is  associated  with  development  of
diabetic macular edema and correlated with macular retinal
thickness in type 2 diabetes. Biochem Biophys Res Commun
2005; 333:679-85. [PMID: 15963467]
32. Chun MY, Hwang HS, Cho HY, Chun HJ, Woo JT, Lee KW,
Nam MS, Baik SH, Kim YS, Park Y. Association of vascular
endothelial  growth  factor  polymorphisms  with
nonproliferative and proliferative diabetic retinopathy. J Clin
Endocrinol Metab 2010; 95:3547-51. [PMID: 20444917]
33. Kangas-Kontio T, Vavuli S, Kakko SJ, Penna J, Savolainen ER,
Savolainen  MJ,  Liinamaa  MJ.  Polymorphism  of  the
manganese superoxide dismutase gene but not of vascular
endothelial growth factor gene is a risk factor for diabetic
retinopathy.  Br  J  Ophthalmol  2009;  93:1401-6.  [PMID:
19628492]
34. Uthra S, Raman R, Mukesh BN, Rajkumar SA, Padmaja KR,
Paul  PG,  Lakshmipathy  P,  Gnanamoorthy  P,  Sharma  T,
McCarty  CA,  Kumaramanickavel  G.  Association  of  vegf
gene  polymorphisms  with  diabetic  retinopathy  in  a  south
indian  cohort.  Ophthalmic  Genet  2008;  29:11-5.  [PMID:
18363167]
35. Wang FH, Liang YB, Peng XY, Wang JJ, Zhang F, Wei WB,
Sun LP, Friedman DS, Wang TY, Wong TY. Risk factors for
diabetic retinopathy in a rural Chinese population with type
2 diabetes: the Handan Eye Study. Acta Ophthalmol (Copenh)
2011; 89:e336-43. [PMID: 21371287]
36. Klein R, Klein BE, Moss SE, Davis MD, DeMets DL. The
wisconsin epidemiologic study of diabetic retinopathy. Ix.
Four-year incidence and progression of diabetic retinopathy
when age at diagnosis is less than 30 years. Arch Ophthalmol
1989; 107:237-43. [PMID: 2916977]
37. Rudnisky CJ, Tennant MT, Weis E, Ting A, Hinz BJ, Greve
MD. Web-based grading of compressed stereoscopic digital
photography versus standard slide film photography for the
Molecular Vision 2011; 17:3088-3096 <http://www.molvis.org/molvis/v17/a332> © 2011 Molecular Vision
3095diagnosis  of  diabetic  retinopathy.  Ophthalmology  2007;
114:1748-54. [PMID: 17368543]
38. Demaine A, Cross D, Millward A. Polymorphisms of the aldose
reductase gene and susceptibility to retinopathy in type 1
diabetes  mellitus.  Invest  Ophthalmol  Vis  Sci  2000;
41:4064-8. [PMID: 11095596]
39. Lepore G, Maglio ML, Nosari I, Dodesini AR, Trevisan R.
Cost-effectiveness  of  two  screening  programs  for
microalbuminuria in type 2 diabetes. Diabetes Care 2002;
25:2103-4. [PMID: 12401764]
40. Barrett JC, Fry B, Maller J, Daly MJ. Haploview: analysis and
visualization  of  LD  and  haplotype  maps.  Bioinformatics
2005; 21:263-5. [PMID: 15297300]
41. Liew  G,  Klein  R,  Wong  TY.  The  role  of  genetics  in
susceptibility to diabetic retinopathy. Int Ophthalmol Clin
2009; 49:35-52. [PMID: 19349785]
42. Uhlmann K, Kovacs P, Boettcher Y, Hammes HP, Paschke R.
Genetics  of  diabetic  retinopathy.  Exp  Clin  Endocrinol
Diabetes 2006; 114:275-94. [PMID: 16868886]
43. Churchill AJ, Carter JG, Lovell HC, Ramsden C, Turner SJ,
Yeung  A,  Escardo  J,  Atan  D.  Vegf  polymorphisms  are
associated  with  neovascular  age-related  macular
degeneration. Hum Mol Genet 2006; 15:2955-61. [PMID:
16940309]
44. Jain L, Vargo CA, Danesi R, Sissung TM, Price DK, Venzon
D, Venitz J, Figg WD. The role of vascular endothelial growth
factor snps as predictive and prognostic markers for major
solid tumors. Mol Cancer Ther 2009; 8:2496-508. [PMID:
19755511]
Molecular Vision 2011; 17:3088-3096 <http://www.molvis.org/molvis/v17/a332> © 2011 Molecular Vision
Articles are provided courtesy of Emory University and the Zhongshan Ophthalmic Center, Sun Yat-sen University, P.R. China.
The print version of this article was created on 28 November 2011. This reflects all typographical corrections and errata to the
article through that date. Details of any changes may be found in the online version of the article.
3096